Research programme: transported prodrugs - Arbor Pharmaceuticals
Alternative Names: Acamprosate prodrug; Propofol prodrug - Arbor Pharmaceuticals; XP 20925Latest Information Update: 26 May 2022
At a glance
- Originator XenoPort
- Developer Arbor Pharmaceuticals; XenoPort
- Class Alkanesulfonic acids; Phenols; Small molecules
- Mechanism of Action GABA A receptor agonists; GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Fragile X syndrome
- No development reported Parkinson's disease
- Discontinued Migraine; Nausea and vomiting
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)